
Opinion|Videos|September 30, 2024
Perspectives on Latest Therapies: Faricimab and Aflibercept 8mg
Author(s)Nikolas London, MD, FACS
Fact checked by: Nikolas London, MD, FACS
Dr. London discusses the implications of faricimab and aflibercept 8 mg in treating retinal diseases, highlighting their mechanisms, efficacy data, and potential to enhance patient outcomes in conditions like wet age-related macular degeneration.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Sharper vision starts here
2
Oculis to launch PIONEER trials for privosegtor in acute optic neuritis and NAION
3
Study finds retinal progenitor cell injections improve outcomes in rat model of diabetic retinopathy
4
iOpeners: Zubair Ansari, MD, shares his global health journey with Nicole Bajic, MD
5